Institute of Molecular Biology, Academia Sinica 2789-9312, 2652-1438

Case	#:	

Pronuclei Microinjection Application Form

Genome Editing Approach

Request date: (IMB s	secretary)	Submission date: (T	CF staff)	Appro	oved date: (TCF manager)
Requester			Institu	ıte	
PI			Phon	e	
Construct Nar	ne				
Preferred Mou Genetic Backgro		□ FVB/NJ □ Other		-	ecial request)
Type of Genor Editing Tool		☐ TALENS (ranscription) ·vitro transcription)
Off-Target cou	nts				
Nature of Const	ruct	☐ Editing only	(Indel : <u>]</u>	<u>[n</u> ser	tion or <u>Del</u> etion)
Expected Pheno	type	☐ Potentially le	ethal		Jnknown

Institute of Molecular Biology, Academia Sinica 2789-9312, 2652-1438

Case #: **Construct Description** □ T7 Promoter for in-vitro **Transcription** □ SP6 **Circular Plasmid** ☐ CsCl₂ Banding □ Qiagen Column **Preparation Method** ☐ Other _____ **Construct Size** ☐ Total Size _____ KB **Enzyme for** Linearization **Gel Photo** (Please paste the gel photo here to Note: Please make sure you satisfy the following requirements. proof your transgenic construct has been completed) Gel electrophoresis should be clear and all the fragments are fully separated Gel photo should be large and the following info should be included: ☐ MW marker (please specify) ☐ Uncut circular plasmid ☐ linearized plasmid All fragments should be clearly indicated by size and name

Institute of Molecular Biology, Academia Sinica 2789-9312, 2652-1438

Case #: Results of in-vitro Tests Note: Please test the efficiency and genotyping approach of the TALENs/CRIPR-Cas9 invitro in advance 1. The TALENs/CRISPR-Cas9 was tested in _____ (cell line name) 2. ☐ The screening was performed using a.

PCR and Restriction Enzyme(RE) Digestion: (RE name) b. PCR and mismatch-specific nuclease: _____ (i.e. T7E1, Surveyor assay...etc.) c. SSA (single strand annealing) assay, tested in _____ (cell line name) d. Others: (Please specify) (Please use a diagram to explain your screening strategy and paste or attach the in-vitro test results) **TCF Note**

Institute of Molecular Biology, Academia Sinica 2789-9312, 2652-1438

Case #:

TALEN, CRISPR/Cas9 Pronuclei Microinjection Checklist

Special Notice

Please check the following questionnaire according to your construct conditions.

Faithful answer will help us to precede the case faster and smoother.

If any of the condition listed below does not fit with your experimental design, please contact TCF manager or TCF committee. Such case might be either treated as special request or rejected from routine TCF services.

21 John Line Constyping
□ In-vitro test and genotyping strategies have been tested successfully
☐ Tested genotyping result(s) is attached with this form

1 Construct and Genetyning

Transgenic Core Facility Institute of Molecular Biology, Academia Sinica 2789-9312, 2652-1438

#:								
	#:	#:	#:	#:	#:	#:	#:	#:

Pronuclear Microinjection Case Evaluation Form

Please fill up the following questionnaire for case evaluation by the transgenic committee. A briefing maybe asked for the final service approval. 1. Has this animal model been made and/or available elsewhere? 2. Has this requested service been submitted elsewhere? 3. Can products from this service be available for other researchers / institutes? 4. For experience sharing and for teaching purpose, can this service be used as a study case in the TCF monthly discussion meeting? 5. Is the production of this transgenic mouse approved by IACUC? Please specify the IACUC protocol number below. Yes. IACUC protocol No.: _____ (Please note that if IACUC protocol hasn't been submitted or approved, TCF will hold the process until it is approved.) P.I. name and affiliation

Date

Signature

Transgenic Core Facility Institute of Molecular Biology, Academia Sinica 2789-9312, 2652-1438

Signature

Pronuclear Microinjection Agreement All TCF services require the agreement and signature from service user with full understanding of all the following statements: 1. I have carefully reviewed the TCF guideline and condition for using the service, and I agree to follow completely to the TCF guideline. 2. I acknowledge that TCF reserves rights to reject or stop my service request at any time point, if the guideline and condition are not fully complied. 3. I agree to acknowledge TCF services in the way of using the following statement in publication. "We acknowledged the Transgenic Core Facility of Academia Sinica in consulting and generating the mice. The transgenic core is funded by Academia Sinica Core Facility and Innovative Instrument Project (AS-CFII-111-
 I have carefully reviewed the TCF guideline and condition for using the service, and I agree to follow completely to the TCF guideline. I acknowledge that TCF reserves rights to reject or stop my service request at any time point, if the guideline and condition are not fully complied. I agree to acknowledge TCF services in the way of using the following statement in publication. "We acknowledged the Transgenic Core Facility of Academia Sinica in consulting and generating the mice. The transgenic core is funded by
 and I agree to follow completely to the TCF guideline. I acknowledge that TCF reserves rights to reject or stop my service request at any time point, if the guideline and condition are not fully complied. I agree to acknowledge TCF services in the way of using the following statement in publication. "We acknowledged the Transgenic Core Facility of Academia Sinica in consulting and generating the mice. The transgenic core is funded by
any time point, if the guideline and condition are not fully complied.3. I agree to acknowledge TCF services in the way of using the following statement in publication. "We acknowledged the Transgenic Core Facility of Academia Sinica in consulting and generating the mice. The transgenic core is funded by
in publication. "We acknowledged the Transgenic Core Facility of Academia Sinica in consulting and generating the mice. The transgenic core is funded by
207)" .
P.I. name and affiliation

Date